SonoSite predicts lower second-half revenue
After a year that saw Bothell, WA-based SonoSite partner with ultrasound giant ATL and that saw the company’s flagship product, a handheld digital ultrasound system, purchased by the 19 member countries of NATO for battlefield use
After a year that saw Bothell, WA-based SonoSite partner with ultrasound giant ATL and that saw the companys flagship product, a handheld digital ultrasound system, purchased by the 19 member countries of NATO for battlefield use (SCAN 4/12/00), SonoSite predicted its second-half revenue will not meet analysts expectations.
SonoSite blamed the slump on a physician strike in South Korea and on a hospital market capital freeze in Taiwan. The company said in a statement, however, that U.S. sales are expected to grow.
The 5-pound portable SonoSite 180 system was developed using licensed ATL technology, and part of the SonoSite system is manufactured by ATL, a Philips Medical System company. ATL Ultrasound is able to bundle sales of the handheld SonoSite 180 with its own ultrasound systems.
SonoSite and ATL Ultrasound signed an agreement in March of this year giving ATL exclusive rights to include SonoSites SonoHeart handheld echocardiology device with sales of its own HDI ultrasound systems and with cardiac catheterization systems from Philips Medical Systems.
The SonoHeart is to be launched this month at the Japanese Society of Cardiology meeting in Osaka. The SonoHeart agreement with ATL covers distribution of products in cardiology-related segments worldwide, with the exception of Japan. Distribution in Japan is covered under an agreement with Olympus Optical.
Can AI Predict Future Lung Cancer Risk from a Single CT Scan?
May 19th 2025In never-smokers, deep learning assessment of single baseline low-dose computed tomography (CT) scans demonstrated a 79 percent AUC for predicting lung cancer up to six years later, according to new research presented today at the American Thoracic Society (ATS) 2025 International Conference.
What if Radiology Turns Out Exactly the Way We Predict it Will?
May 19th 2025Whether it is reimbursement cuts or continued attempts to push non-radiologist image interpretation, where do we draw the line between inspired protest and misspent energy criticizing things that are doomed to fail or things we have no control over?
What a New PSMA PET/CT Study Reveals About Local PCa Treatment and High-Risk Recurrence
May 16th 2025For patients at high-risk for biochemical recurrence of prostate cancer, PSMA PET/CT findings revealed that 77 percent had one or more prostate lesions after undergoing local radiation therapy or radical prostatectomy, according to a recent study.
